SOURCE: Radius Health, Inc.

Radius Health, Inc.

May 05, 2014 08:00 ET

Radius Announces Scientific Presentations at the 40th European Calcified Tissue Society (ECTS) Congress and at the Joint Meeting of the International Society of Endocrinology and the Endocrine Society (ICE/ENDO 2014)

CAMBRIDGE, MA--(Marketwired - May 5, 2014) - Radius Health Announces Scientific Presentations at the 40th European Calcified Tissue Society (ECTS) Congress and at the joint meeting of the International Society of Endocrinology and the Endocrine Society (ICE/ENDO 2014)

Radius Health, Inc. will present scientific data from studies conducted with abaloparatide (BA058) at the European Calcified Tissue Society (ECTS) Congress, in Prague, Czech Republic, May 17 - 20, 2014. Four abstracts have been accepted for presentation at the Congress.

Abstracts are available on-line at http://www.ectscongress.org/2014/abstractOnline.aspx to registered attendees of the ECTS Congress.

Radius will also present at the joint meeting of the International Society of Endocrinology and the Endocrine Society (ICE/ENDO 2014) in Chicago, Illinois, June 21-24, 2014.

Abstracts are available to view on-line https://endo.confex.com/endo/2014endo/webprogram/programs.html

About Radius Health

Radius Health, Inc. is a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases. The company's lead development candidate is abaloparatide (BA058), a bone anabolic for delivery via subcutaneous injection that is currently in Phase 3 development for the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an abaloparatide transdermal patch for osteoporosis and RAD1901 for estrogen-driven breast cancer brain metastases.